bioMérieux S.A
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; … Read more
bioMérieux S.A (BMXMF) - Total Assets
Latest total assets as of June 2025: $5.37 Billion USD
Based on the latest financial reports, bioMérieux S.A (BMXMF) holds total assets worth $5.37 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
bioMérieux S.A - Total Assets Trend (2005–2024)
This chart illustrates how bioMérieux S.A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
bioMérieux S.A - Asset Composition Analysis
Current Asset Composition (December 2024)
bioMérieux S.A's total assets of $5.37 Billion consist of 43.4% current assets and 56.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.8% |
| Accounts Receivable | $857.60 Million | 14.9% |
| Inventory | $1.04 Billion | 18.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $492.00 Million | 8.5% |
| Goodwill | $730.40 Million | 12.7% |
Asset Composition Trend (2005–2024)
This chart illustrates how bioMérieux S.A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: bioMérieux S.A's current assets represent 43.4% of total assets in 2024, a decrease from 52.7% in 2005.
- Cash Position: Cash and equivalents constituted 7.8% of total assets in 2024, up from 2.3% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 20.0% of total assets, an increase from 9.0% in 2005.
- Asset Diversification: The largest asset category is inventory at 18.0% of total assets.
bioMérieux S.A Competitors by Total Assets
Key competitors of bioMérieux S.A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
bioMérieux S.A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - bioMérieux S.A generates 0.69x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, bioMérieux S.A generates $7.49 in net profit.
bioMérieux S.A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.27 | 2.21 | 1.49 |
| Quick Ratio | 1.30 | 1.20 | 1.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.27 Billion | $ 1.21 Billion | $ 584.70 Million |
bioMérieux S.A - Advanced Valuation Insights
This section examines the relationship between bioMérieux S.A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.85 |
| Latest Market Cap to Assets Ratio | 0.97 |
| Asset Growth Rate (YoY) | 9.7% |
| Total Assets | $5.77 Billion |
| Market Capitalization | $5.61 Billion USD |
Valuation Analysis
Near Book Valuation: The market values bioMérieux S.A's assets close to their book value ( 0.97x), suggesting investors view the company's assets at approximately fair value.
Positive Asset Growth: bioMérieux S.A's assets grew by 9.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for bioMérieux S.A (2005–2024)
The table below shows the annual total assets of bioMérieux S.A from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $5.77 Billion | +9.71% |
| 2023-12-31 | $5.26 Billion | +1.40% |
| 2022-12-31 | $5.19 Billion | +12.34% |
| 2021-12-31 | $4.62 Billion | +17.54% |
| 2020-12-31 | $3.93 Billion | +3.86% |
| 2019-12-31 | $3.78 Billion | +11.57% |
| 2018-12-31 | $3.39 Billion | +13.36% |
| 2017-12-31 | $2.99 Billion | -1.28% |
| 2016-12-31 | $3.03 Billion | +9.20% |
| 2015-12-31 | $2.77 Billion | +7.48% |
| 2014-12-31 | $2.58 Billion | +17.48% |
| 2013-12-31 | $2.20 Billion | +19.82% |
| 2012-12-31 | $1.83 Billion | +4.03% |
| 2011-12-31 | $1.76 Billion | +21.64% |
| 2010-12-31 | $1.45 Billion | +15.00% |
| 2009-12-31 | $1.26 Billion | +5.93% |
| 2008-12-31 | $1.19 Billion | +19.11% |
| 2007-12-31 | $998.40 Million | +6.26% |
| 2006-12-31 | $939.60 Million | +3.70% |
| 2005-12-31 | $906.10 Million | -- |